CA2106197A1 - Methode de traitement et de prevention de la toxicomanie - Google Patents

Methode de traitement et de prevention de la toxicomanie

Info

Publication number
CA2106197A1
CA2106197A1 CA002106197A CA2106197A CA2106197A1 CA 2106197 A1 CA2106197 A1 CA 2106197A1 CA 002106197 A CA002106197 A CA 002106197A CA 2106197 A CA2106197 A CA 2106197A CA 2106197 A1 CA2106197 A1 CA 2106197A1
Authority
CA
Canada
Prior art keywords
caring
substance
alkyl
individual
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002106197A
Other languages
English (en)
Inventor
Montford F. Piercey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2106197A1 publication Critical patent/CA2106197A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002106197A 1991-04-26 1992-04-13 Methode de traitement et de prevention de la toxicomanie Abandoned CA2106197A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69323891A 1991-04-26 1991-04-26
US693,238 1991-04-26

Publications (1)

Publication Number Publication Date
CA2106197A1 true CA2106197A1 (fr) 1992-10-27

Family

ID=24783880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106197A Abandoned CA2106197A1 (fr) 1991-04-26 1992-04-13 Methode de traitement et de prevention de la toxicomanie

Country Status (5)

Country Link
EP (1) EP0581865A1 (fr)
JP (1) JPH06506951A (fr)
AU (1) AU1915192A (fr)
CA (1) CA2106197A1 (fr)
WO (1) WO1992019234A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
AR075442A1 (es) * 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
TW201319049A (zh) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途
KR20160062165A (ko) 2013-10-17 2016-06-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 아미노테트랄린 및 아미노인단 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65501A (en) * 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds

Also Published As

Publication number Publication date
EP0581865A1 (fr) 1994-02-09
WO1992019234A3 (fr) 1993-01-07
JPH06506951A (ja) 1994-08-04
AU1915192A (en) 1992-12-21
WO1992019234A2 (fr) 1992-11-12

Similar Documents

Publication Publication Date Title
CA2106197A1 (fr) Methode de traitement et de prevention de la toxicomanie
EP0163697B1 (fr) Methode rapide permettant d'interrompre le syndrome d'accoutumance aux narcotiques
Henderson Designer drugs: past history and future prospects
US12083090B2 (en) Methods of using low-dose doxepin for the improvement of sleep
Patel Mechanism of action of cathinone: the active ingredient of Khat (Catha Edulis
Fink et al. Naloxone in heroin dependence
Papsun et al. The trouble with kratom: analytical and interpretative issues involving mitragynine
US20090042972A1 (en) Methods of using low-dose doxepin for the improvement of sleep
US20090042971A1 (en) Method of using low-dose doxepin for the improvement of sleep
CN102695502A (zh) 用于治疗药瘾和改善药瘾相关行为的组合物
EP0563336A1 (fr) Composition pharmaceutique contenant de l'acide gamma-hydroxybutyrique ou sa lactone et utilisee dans le traitement de la toxicomanie et des troubles nutritionnels
US20040053994A1 (en) Laetispicine and laetispicine analogues, methods of use and preparation
CA2118512C (fr) Agents utilises dans le traitement des toxicomanies
CA2443346A1 (fr) Nouveaux composes anticholinergiques et procedes d'utilisation
Beckett et al. 2 The Testing and Development of Analgesic Drugs
Nelson Medical problems associated with addiction to opioid drugs
Gay et al. Some pharmacological perspectives on the opiate narcotics with special consideration of heroin
Harris Analgetics–Strong and Weak
Campus IBOGAINE (IBOGA TABERNANTHE) AS A POTENTIAL ANTI-ADDICTIVE TREATMENT IN THE PIPELINE: A REVIEW
KR100491027B1 (ko) 물질남용질환치료를위한피리딜-및피리미딜-피페라진
Du et al. Erycibe Alkaloid II
JATLOW JACOB LOKE and RICHARD ROWLEY Yale University School of Medicine New Haven, Connecticut
Albert Steric factors
Misevic et al. The Use of Akineton for Parkinsonism
Qureshi et al. Pharmacotherapies of addiction

Legal Events

Date Code Title Description
FZDE Dead